Latest Healthcare News

Integral Diagnostics has confirmed Jason Martinez will take over as Managing Director and CEO in August 2026, with Dr Ian Kadish remaining in charge until then to ensure a smooth transition.

Recce Pharmaceuticals has expanded its intellectual property footprint with a newly granted patent in Brazil, protecting its innovative synthetic anti-infectives against a broad range of infections. This milestone strengthens Recce’s position in one of South America’s largest antibiotic markets.

Emyria Limited is on track to open its first Empax clinic in Victoria by Q2 2026, having secured key operational milestones including a trained clinical workforce and dual reimbursement pathways.

BlinkLab has enrolled its first participant in the pivotal FDA 510(k) validation study for its autism diagnostic aid, BlinkLab Dx1, aiming for regulatory submission by the end of 2026.

Radiopharm Theranostics reports promising second interim Phase 2b results for RAD 101, showing 90% concordance with MRI in detecting brain metastases and encouraging sensitivity and specificity trends.

Echo IQ has strengthened its partnership with Mayo Clinic to distribute its AI-driven heart failure diagnostic tool, EchoSolv HF, pending FDA clearance. The expanded agreement offers a scalable commercial pathway across a vast US hospital network.

Cyclopharm has secured a multi-site agreement with Northwestern Medicine, marking a major expansion into Chicago’s healthcare market and reinforcing its US growth strategy.

BlinkLab’s smartphone-based Dx1 autism screening technology has been selected for Morocco’s government-funded national early screening program, marking a major milestone in digital health adoption and autism care.

Amplia Therapeutics reports a remarkable 7.8% complete response rate and improved survival in its ACCENT pancreatic cancer trial, positioning narmafotinib as a promising new treatment option.

Cyclopharm has secured a significant multi-site agreement with the University of Pennsylvania Health System, marking a major step in its US expansion with installations across 11 clinical locations.

Cochlear Limited has updated its dividend details, confirming a fully franked ordinary dividend of AUD 2.15 per share for the six months ending December 2025, payable in April 2026 across multiple currencies.

Cleo Diagnostics has expanded its ovarian cancer biomarker panel from five to eight markers, enhancing test reliability and gearing up for FDA submission. A manufacturing deal is imminent, setting the stage for commercial rollout.